Labnovation Analyzer LD-560 For HbA1c Testing HPLC Method IFCC&NGSP Certificated Latest HbA1c Analyzer

Labnovation Analyzer LD-560 For HbA1c Testing HPLC Method IFCC&NGSP Certificated Latest HbA1c Analyzer

Intended Use

The Fully Automated HbA1c Analyzer is used in conjunction with suitable reagents for the quantitative detection of glycosylated hemoglobin (HbA1c) in human blood.

Specifications

Principle

Using high performance liquid chromatography (HPLC), the stationary phase used is a weakly acidic cation exchanger. Glycosylation of hemoglobin will result in the loss of cations on the surface of hemoglobin without being charged, and non-glycosylated hemoglobin has a positive charge.

Feature

• No Sample Pre-treatment
• Fully automated operation saves time and labor
• Automatic Primary tube sampling with cap puncture
• Auto identificate the whole blood or lyse
• Batch sampling offer flexibility in workflow

Reagents and Consumables

• Eluent A/Eluent B/Eluent C: Adjusts the pH of the solution for the elution of glycosylated hemoglobin and non-glycated hemoglobin.
• Hemolysis Reagent: Used to dissolve red blood cells and release hemoglobin.
• Chromatography column: Used for separation and elution of glycosylated hemoglobin and non-glycated hemoglobin.
• Filter: Used to initially filter the sample after hemolysis.
• Paper Rolls: Prints a report of the test results.

Performance Parameters

• Reporting unit: Glycosylated hemoglobin (HbA1c) is reported in NGSP (%) and IFCC units (mmol/mol).

• Accuracy: The accuracy is tested with reference materials as samples, and the relative deviation of the test results should be within ±5%.

• Stability Within 8 hours after the analyzer is turned on and stabilized, the same normal sample is tested, and the relative deviation of the test results is not more than ±3.0%.

• Carrying pollution: The carrying pollution rate of the analyzer should not be greater than 2.0%.

Clinical Application of HbA1c

• Blood Sugar Monitoring: For patients with high blood sugar, HbA1c should be checked regularly, so as to know whether their blood sugar control in the past 2-3 months is ideal and whether the treatment plan is effective.
• Complication risk control: HbA1c is controlled at 6.5%, which can greatly reduce diabetic patients risk of various complications, thus greatly improving the patient‘s quality of life.
• Health Checkup Screening: The incidence of diabetes in China has been as high as 11%, especially those with hypertension are prone to diabetes.

FAQ

• What's your product lead time?

Normally all our medical equipment are in stock, so we can deliver goods within 5 workdays after receipt payment.

• How to maintenance the product if it has problem?

We have professional engineers,they will solve your problem by communicating with skype or phone.

• What about the price level?

Our prices are competitive compared with those at the same quality level, and we keep striving to provide the best pricing to our customers.

Certificated

Labnovation Technologies, Inc. is an original manufacturer established in Shenzhen, China since 2001. We are dedicated in developing and manufacturing IVD instruments and reagents including HbA1c analyzer and reagents, rapid test reader & reagents, hematology reagents, clinical chemistry reagents, electrolyte reagents, wash solution and urine test reagents.

Labnovation products are developed in house, tested extensively in clinics and passed strict quality controls. All of our products are CE marked and approved by SFDA. In the past 15 years, our products have been exported to 110 different countries and used in 8000 hospitals worldwide. We provide both ready-to-use final products and bulk OEM reagents, including ready-to-use reagents, concentrated, and powder.

With an investment of 10% of our annual sales into R&D, we release new products every years. We win more and more domestic and international cooperation by company reputation and products quality while we actively take part in fairs like MEDICA,AACC, ARBA HEALTH and so on through which we are well-known by the companies in this field.